-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA or Agency) is withdrawing approval of six abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
DATES:
Approval is withdrawn as of January 12, 2022.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, Martha.Nguyen@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.
Application No. Drug Applicant ANDA 202603 Methoxsalen Capsules, 10 milligrams (mg) Actavis LLC, (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Pkwy., Bldg. A, Parsippany, NJ 07054. ANDA 205274 Amoxicillin Tablets, 125 mg and 250 mg Hikma Pharmaceuticals LLC, 1809 Wilson Rd., Columbus, OH 43228. ANDA 205513 Carisoprodol Tablets, 250 mg and 350 mg Strides Pharma Global Pte. Limited, U.S. Agent, Strides Pharma Inc., 2 Tower Center Blvd., Suite 1102, East Brunswick, NJ 08816. ANDA 206410 Itraconazole Capsules, 100 mg Do. ANDA 207536 Flucytosine Capsules, 250 mg and 500 mg Do. ANDA 208227 Dutasteride Capsules, 0.5 mg Do. Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of January 12, 2022. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on January 12, 2022, may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
Start SignatureDated: December 7, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021-26892 Filed 12-10-21; 8:45 am]
BILLING CODE 4164-01-P
Document Information
- Published:
- 12/13/2021
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 2021-26892
- Dates:
- Approval is withdrawn as of January 12, 2022.
- Pages:
- 70852-70852 (1 pages)
- Docket Numbers:
- Docket No. FDA-2021-N-1287
- PDF File:
- 2021-26892.pdf
- Supporting Documents:
- » Actavis LLC, et al.; Withdrawal of Approval of Six Abbreviated New Drug Applications